Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Clene Inc. Regulatory Filings 2024

Sep 30, 2024

34487_prs_2024-09-30_96b3cb2a-137f-4227-b046-11387e4d65ce.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

424B5 1 clnn20240930_424b5.htm FORM 424B5 clnn20240930_424b5.htm Generated by ThunderDome Portal - 9/30/2024 4:51:53 AM

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-264299

PROSPECTUS SUPPLEMENT No. 2

(To Prospectus dated April 26, 2022 and

Prospectus Supplement dated November 7, 2023 and

Prospectus Supplement No. 1 dated May 8, 2024)

Clene Inc.

This Supplement No. 2 to the Prospectus Supplement supplements and amends the Prospectus Supplement dated November 7, 2023 (the “Prospectus Supplement”) and Supplement No. 1 to the Prospectus Supplement dated May 8, 2024 (“Supplement No. 1”) filed by Clene Inc. (“we,” “us,” and “our”). This Supplement No. 2 to the Prospectus Supplement should be read in conjunction with the Prospectus Supplement, Supplement No. 1 and the base prospectus dated April 26, 2022 (the “Base Prospectus”).

We have previously entered into a Equity Distribution Agreement (the “ATM Agreement”), dated April 14, 2022, with Canaccord Genuity LLC (“Canaccord”), pursuant to which Canaccord acts as sales agent pursuant to that certain “at-the-market offering.”

We filed the Prospectus Supplement to register the offer and sale of $15,000,000 of shares of our common stock issuable pursuant to the ATM Agreement, and we filed Supplement No. 1 to reduce the maximum aggregate gross sales price of our common stock that may be offered and sold pursuant to the ATM Agreement to $12,300,000 of shares of our common stock. We have offered, issued and sold shares of our common stock pursuant to the ATM Agreement, Prospectus Supplement, and Supplement No. 1 for gross proceeds of approximately $2,098,857. An aggregate of approximately $12,901,143 of shares of our common stock remained to be sold pursuant to the ATM Agreement, Prospectus Supplement and Supplement No. 1.

The purpose of this Supplement No. 2 is to terminate, effective on the date of this Supplement No. 2, the offering of the approximately $12,901,143 of shares of our common stock that were not sold pursuant to the ATM Agreement, Prospectus Supplement and Supplement No. 1 prior to its termination. Other than the termination of the Prospectus Supplement, the ATM Agreement remains in full force and effect.

The date of this Supplement No. 2 to the Prospectus Supplement is September 30, 2024.